background. the aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naive to antiretroviral treatment (ICONA).methods. all patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology.results. patients who were HBcAb+/HCV-/HBs antigen (HBsAg)- and HCV+/HBcAb+/HBsAg- or HBsAg+/HBcAb+/ HCV- had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P < .0001). a cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg- patients (HR, 7.2; 95% CI, 3 8-13.64). conclusions. HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg- subjects. a careful monitoring for signs of previous HBV infection is needed in this kind of patients.
Malagnino, V., Cerva, C., Cingolani, A., Ceccherini-Silberstein, F., Vergori, A., Cuomo, G., et al. (2021). HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. OPEN FORUM INFECTIOUS DISEASES, 8(1), 1-8 [10.1093/ofid/ofaa566].
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
Malagnino V;Ceccherini-Silberstein F;Andreoni M;Sarmati L;
2021-01-01
Abstract
background. the aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis (fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naive to antiretroviral treatment (ICONA).methods. all patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology.results. patients who were HBcAb+/HCV-/HBs antigen (HBsAg)- and HCV+/HBcAb+/HBsAg- or HBsAg+/HBcAb+/ HCV- had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P < .0001). a cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/HBsAg- patients (HR, 7.2; 95% CI, 3 8-13.64). conclusions. HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/HBsAg- subjects. a careful monitoring for signs of previous HBV infection is needed in this kind of patients.File | Dimensione | Formato | |
---|---|---|---|
ofaa566.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
230.01 kB
Formato
Adobe PDF
|
230.01 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.